Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.

Lindberg, James M; Newhook, Timothy E; Adair, Sara J; Walters, Dustin M; Kim, Alison J; Stelow, Edward B; Parsons, J Thomas; Bauer, Todd W

Lindberg, James M; Newhook, Timothy E; Adair, Sara J; Walters, Dustin M; Kim, Alison J; Stelow, Edward B; Parsons, J Thomas; Bauer, Todd W.

Affiliation

Lindberg JM; Department of Surgery, University of Virginia Health System, Charlottesville, VA, 22908 USA.
Newhook TE; Department of Surgery, University of Virginia Health System, Charlottesville, VA, 22908 USA.
Adair SJ; Department of Surgery, University of Virginia Health System, Charlottesville, VA, 22908 USA.
Walters DM; Department of Surgery, University of Virginia Health System, Charlottesville, VA, 22908 USA.
Kim AJ; Department of Surgery, University of Virginia Health System, Charlottesville, VA, 22908 USA.
Stelow EB; Department of Pathology, University of Virginia Health System, Charlottesville, VA, 22908 USA.
Parsons JT; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA, 22908 USA.
Bauer TW; Department of Surgery, University of Virginia Health System, Charlottesville, VA, 22908 USA. Electronic address: twb7f@virginia.edu.

Neoplasia ; 16(7): 562-71, 2014 Jul.

Article in En | MEDLINE | ID: mdl-25117978

Subject(s)

Antibodies, Monoclonal, Humanized/pharmacology; Antibodies, Monoclonal/pharmacology; Antineoplastic Agents/pharmacology; Mitogen-Activated Protein Kinases/antagonists & inhibitors; Pancreatic Neoplasms/metabolism; Pyridones/pharmacology; Pyrimidinones/pharmacology; Animals; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal, Humanized/administration & dosage; Antineoplastic Agents/administration & dosage; Carcinoma, Pancreatic Ductal/drug therapy; Carcinoma, Pancreatic Ductal/metabolism; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors/antagonists & inhibitors; ErbB Receptors/metabolism; Humans; Male; Mitogen-Activated Protein Kinases/metabolism; Mutation; Pancreatic Neoplasms/drug therapy; Pancreatic Neoplasms/genetics; Pancreatic Neoplasms/pathology; Panitumumab; Phosphorylation; Protein Kinase Inhibitors/administration & dosage; Protein Kinase Inhibitors/pharmacology; Proto-Oncogene Proteins c-akt/metabolism; Pyridones/administration & dosage; Pyrimidinones/administration & dosage; Receptor, ErbB-2/antagonists & inhibitors; Receptor, ErbB-2/metabolism; Signal Transduction/drug effects; Trastuzumab; Tumor Burden/drug effects; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Pyridones / Pyrimidinones / Mitogen-Activated Protein Kinases / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic_studies Language: En Journal: Neoplasia Journal subject: NEOPLASIAS Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google